23rd Jul 2026 10:11
(Alliance News) - AstraZeneca PLC on Thursday said a combination with its Etcamah drug has been approved for treatment of breast cancer in the EU.
The European Commission acted upon the positive opinion of the Committee for Medicinal Products for Human Use, the Cambridge, England-based drug maker said. This followed positive results from the Serena-6 phase III trial, which showed a 56% reduction in the risk of disease progression in advanced estrogen receptor-positive breast cancer.
Etcamah, whose generic name is camizestrant, was tested in combination with a cyclin-dependent kinase 4/6 inhibitor.
AstraZeneca noted that the Etcamah combo also has been approved in Japan, the UAE and Saudi Arabia, based on the Serena-6 trial results.
AstraZeneca noted that breast cancer remains the leading cause of cancer death among women in Europe, with more than 140,000 deaths and more than 540,000 patients diagnosed in 2024.
Shares were down 0.6% to 12,628.00 pence in London on Thursday.
By Tom Waite, Alliance News editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca